- Home
- KNOP vs CHRS Comparison
KNOP vs CHRS Comparison
Compare KNOP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | CHRS |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 186.0M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KNOP | CHRS |
|---|---|---|
| Price | $10.45 | $1.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $4.51 |
| AVG Volume (30 Days) | 148.9K | ★ 987.2K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 1.17 | ★ 1.34 |
| Revenue | ★ $352,712,000.00 | $277,728,000.00 |
| Revenue This Year | $13.56 | N/A |
| Revenue Next Year | $2.42 | $67.29 |
| P/E Ratio | $8.93 | ★ $1.04 |
| Revenue Growth | 17.65 | ★ 152.07 |
| 52 Week Low | $5.28 | $0.71 |
| 52 Week High | $10.99 | $1.89 |
Technical Indicators
Market Signals| Indicator | KNOP | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 52.09 |
| Support Level | $10.58 | $1.31 |
| Resistance Level | $10.89 | $1.45 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 53.04 | 72.29 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.